Predictive care startup Clew gets emergency FDA approval to help treat Covid-19 patients
Clew’s system can assist medical teams in remotely identifying patients who are likely to experience common coronavirus complications, including respiratory failure and hemodynamic instability
In January, Clew announced a $10 million round bringing its total funding raised to date to $20 million.
"Clew is officially the first and only AI powered device authorized by the FDA to provide early identification of respiratory failure and hemodynamic instability for Covid-19 patients,” Ittai Harel, managing general partner at Pitango Health, one of Clew’s main backers, said in a statement. “Clew’s system was a key component in Covid-19 command centers in leading hospitals in Israel, and forward looking, thrives to become an integral part of healthcare management worldwide, as we enter the new normal," he added.